Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
Add more filters










Publication year range
2.
Cell Res ; 26(7): 761-74, 2016 07.
Article in English | MEDLINE | ID: mdl-27241552

ABSTRACT

Breast cancer is the most common female cancer, affecting approximately one in eight women during their life-time. Besides environmental triggers and hormones, inherited mutations in the breast cancer 1 (BRCA1) or BRCA2 genes markedly increase the risk for the development of breast cancer. Here, using two different mouse models, we show that genetic inactivation of the key osteoclast differentiation factor RANK in the mammary epithelium markedly delayed onset, reduced incidence, and attenuated progression of Brca1;p53 mutation-driven mammary cancer. Long-term pharmacological inhibition of the RANK ligand RANKL in mice abolished the occurrence of Brca1 mutation-driven pre-neoplastic lesions. Mechanistically, genetic inactivation of Rank or RANKL/RANK blockade impaired proliferation and expansion of both murine Brca1;p53 mutant mammary stem cells and mammary progenitors from human BRCA1 mutation carriers. In addition, genome variations within the RANK locus were significantly associated with risk of developing breast cancer in women with BRCA1 mutations. Thus, RANKL/RANK control progenitor cell expansion and tumorigenesis in inherited breast cancer. These results present a viable strategy for the possible prevention of breast cancer in BRCA1 mutant patients.


Subject(s)
BRCA1 Protein/genetics , Breast Neoplasms/genetics , RANK Ligand/metabolism , Receptor Activator of Nuclear Factor-kappa B/metabolism , Animals , BRCA2 Protein/genetics , Breast Neoplasms/drug therapy , Breast Neoplasms/metabolism , Breast Neoplasms/pathology , Cell Proliferation/drug effects , Cells, Cultured , DNA Damage/drug effects , Epithelial Cells/cytology , Epithelial Cells/drug effects , Epithelial Cells/metabolism , Estrogen Receptor alpha/metabolism , Female , Genotype , Humans , Mice , Mice, Inbred C57BL , Mice, Transgenic , RANK Ligand/antagonists & inhibitors , RANK Ligand/genetics , Receptor Activator of Nuclear Factor-kappa B/genetics , Receptors, Progesterone/metabolism , Recombinant Fusion Proteins/pharmacology , Recombinant Fusion Proteins/therapeutic use , Stem Cells/cytology , Stem Cells/metabolism , Tumor Suppressor Protein p53/genetics , Tumor Suppressor Protein p53/metabolism
3.
Cell Rep ; 15(7): 1481-1492, 2016 05 17.
Article in English | MEDLINE | ID: mdl-27160902

ABSTRACT

The HECT domain E3 ligase HACE1 has been identified as a tumor suppressor in multiple cancers. Here, we report that HACE1 is a central gatekeeper of TNFR1-induced cell fate. Genetic inactivation of HACE1 inhibits TNF-stimulated NF-κB activation and TNFR1-NF-κB-dependent pathogen clearance in vivo. Moreover, TNF-induced apoptosis was impaired in hace1 mutant cells and knockout mice in vivo. Mechanistically, HACE1 is essential for the ubiquitylation of the adaptor protein TRAF2 and formation of the apoptotic caspase-8 effector complex. Intriguingly, loss of HACE1 does not impair TNFR1-mediated necroptotic cell fate via RIP1 and RIP3 kinases. Loss of HACE1 predisposes animals to colonic inflammation and carcinogenesis in vivo, which is markedly alleviated by genetic inactivation of RIP3 kinase and TNFR1. Thus, HACE1 controls TNF-elicited cell fate decisions and exerts tumor suppressor and anti-inflammatory activities via a TNFR1-RIP3 kinase-necroptosis pathway.


Subject(s)
Cell Lineage , Receptors, Tumor Necrosis Factor, Type I/metabolism , Tumor Suppressor Proteins/metabolism , Ubiquitin-Protein Ligases/metabolism , Animals , Apoptosis/drug effects , Caspase 8/metabolism , Cell Lineage/drug effects , Colitis/metabolism , Colitis/pathology , Colonic Neoplasms/metabolism , Colonic Neoplasms/pathology , Dextran Sulfate , Embryo, Mammalian/cytology , Enzyme Activation/drug effects , Fibroblasts/drug effects , Fibroblasts/metabolism , Gene Deletion , Mice, Inbred C57BL , Mutation/genetics , NF-kappa B/metabolism , Necrosis , Receptor-Interacting Protein Serine-Threonine Kinases/metabolism , TNF Receptor-Associated Factor 2/metabolism , Tumor Necrosis Factor-alpha/pharmacology , Ubiquitination/drug effects
4.
Nat Genet ; 46(9): 1028-33, 2014 Sep.
Article in English | MEDLINE | ID: mdl-25129145

ABSTRACT

Neutrophils are key innate immune effector cells that are essential to fighting bacterial and fungal pathogens. Here we report that mice carrying a hematopoietic lineage-specific deletion of Jagn1 (encoding Jagunal homolog 1) cannot mount an efficient neutrophil-dependent immune response to the human fungal pathogen Candida albicans. Global glycobiome analysis identified marked alterations in the glycosylation of proteins involved in cell adhesion and cytotoxicity in Jagn1-deficient neutrophils. Functional analysis confirmed marked defects in neutrophil migration in response to Candida albicans infection and impaired formation of cytotoxic granules, as well as defective myeloperoxidase release and killing of Candida albicans. Treatment with granulocyte/macrophage colony-stimulating factor (GM-CSF) protected mutant mice from increased weight loss and accelerated mortality after Candida albicans challenge. Notably, GM-CSF also restored the defective fungicidal activity of bone marrow cells from humans with JAGN1 mutations. These data directly identify Jagn1 (JAGN1 in humans) as a new regulator of neutrophil function in microbial pathogenesis and uncover a potential treatment option for humans.


Subject(s)
Candidiasis/immunology , Membrane Proteins/immunology , Neutrophils/immunology , Animals , Bone Marrow Cells/immunology , Bone Marrow Cells/metabolism , Bone Marrow Cells/microbiology , Candida albicans , Candidiasis/drug therapy , Candidiasis/metabolism , Candidiasis/microbiology , Glycosylation , Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology , Humans , Male , Membrane Proteins/metabolism , Mice , Neutrophils/microbiology
5.
PLoS One ; 6(11): e26248, 2011.
Article in English | MEDLINE | ID: mdl-22087225

ABSTRACT

PDZ (Post-synaptic density, 95 kDa, Discs large, Zona Occludens-1) domains are protein interaction domains that bind to the carboxy-terminal amino acids of binding partners, heterodimerize with other PDZ domains, and also bind phosphoinositides. PDZ domain containing proteins are frequently involved in the assembly of multi-protein complexes and clustering of transmembrane proteins. LNX1 (Ligand of Numb, protein X 1) is a RING (Really Interesting New Gene) domain-containing E3 ubiquitin ligase that also includes four PDZ domains suggesting it functions as a scaffold for a multi-protein complex. Here we use a human protein array to identify direct LNX1 PDZ domain binding partners. Screening of 8,000 human proteins with isolated PDZ domains identified 53 potential LNX1 binding partners. We combined this set with LNX1 interacting proteins identified by other methods to assemble a list of 220 LNX1 interacting proteins. Bioinformatic analysis of this protein list was used to select interactions of interest for future studies. Using this approach we identify and confirm six novel LNX1 binding partners: KCNA4, PAK6, PLEKHG5, PKC-alpha1, TYK2 and PBK, and suggest that LNX1 functions as a signalling scaffold.


Subject(s)
Ubiquitin-Protein Ligases/chemistry , Computational Biology , Drug Evaluation, Preclinical , Humans , PDZ Domains , Protein Binding , Protein Interaction Mapping , Signal Transduction , Ubiquitin-Protein Ligases/metabolism , Ubiquitin-Protein Ligases/physiology
6.
Cell ; 131(3): 476-91, 2007 Nov 02.
Article in English | MEDLINE | ID: mdl-17981116

ABSTRACT

Type-2 diabetes results from the development of insulin resistance and a concomitant impairment of insulin secretion. Recent studies place altered mitochondrial oxidative phosphorylation (OxPhos) as an underlying genetic element of insulin resistance. However, the causative or compensatory nature of these OxPhos changes has yet to be proven. Here, we show that muscle- and liver-specific AIF ablation in mice initiates a pattern of OxPhos deficiency closely mimicking that of human insulin resistance, and contrary to current expectations, results in increased glucose tolerance, reduced fat mass, and increased insulin sensitivity. These results are maintained upon high-fat feeding and in both genetic mosaic and ubiquitous OxPhos-deficient mutants. Importantly, the effects of AIF on glucose metabolism are acutely inducible and reversible. These findings establish that tissue-specific as well as global OxPhos defects in mice can counteract the development of insulin resistance, diabetes, and obesity.


Subject(s)
Apoptosis Inducing Factor/deficiency , Diabetes Mellitus/prevention & control , Gene Deletion , Gene Targeting , Mitochondria/metabolism , Obesity/prevention & control , Oxidative Phosphorylation , Animals , Apoptosis Inducing Factor/genetics , Cell Respiration/drug effects , Diabetes Mellitus/genetics , Diabetes Mellitus/metabolism , Diet/adverse effects , Glucose/metabolism , Insulin/pharmacology , Liver/cytology , Liver/drug effects , Liver/metabolism , Mice , Mice, Knockout , Mitochondria/drug effects , Mosaicism/drug effects , Muscles/cytology , Muscles/drug effects , Muscles/metabolism , Obesity/genetics , Obesity/metabolism , Organ Specificity/drug effects , Oxidative Phosphorylation/drug effects , Phenotype , Substrate Specificity/drug effects
7.
Nat Med ; 13(9): 1060-9, 2007 Sep.
Article in English | MEDLINE | ID: mdl-17694067

ABSTRACT

Transformation and cancer growth are regulated by the coordinate actions of oncogenes and tumor suppressors. Here, we show that the novel E3 ubiquitin ligase HACE1 is frequently downregulated in human tumors and maps to a region of chromosome 6q21 implicated in multiple human cancers. Genetic inactivation of HACE1 in mice results in the development of spontaneous, late-onset cancer. A second hit from either environmental triggers or genetic heterozygosity of another tumor suppressor, p53, markedly increased tumor incidence in a Hace1-deficient background. Re-expression of HACE1 in human tumor cells directly abrogates in vitro and in vivo tumor growth, whereas downregulation of HACE1 via siRNA allows non-tumorigenic human cells to form tumors in vivo. Mechanistically, the tumor-suppressor function of HACE1 is dependent on its E3 ligase activity and HACE1 controls adhesion-dependent growth and cell cycle progression during cell stress through degradation of cyclin D1. Thus, HACE1 is a candidate chromosome 6q21 tumor-suppressor gene involved in multiple cancers.


Subject(s)
Chromosomes, Human, Pair 6 , Genes, Tumor Suppressor , Kidney Neoplasms/genetics , Ubiquitin-Protein Ligases/genetics , Wilms Tumor/genetics , Animals , Ankyrin Repeat/genetics , Chromosome Mapping , DNA Methylation , Gene Expression Regulation, Neoplastic , Genetic Predisposition to Disease , Humans , Mice , Mice, Mutant Strains , RNA, Messenger/genetics
8.
Circ Res ; 101(4): e32-42, 2007 Aug 17.
Article in English | MEDLINE | ID: mdl-17673668

ABSTRACT

Apelin constitutes a novel endogenous peptide system suggested to be involved in a broad range of physiological functions, including cardiovascular function, heart development, control of fluid homeostasis, and obesity. Apelin is also a catalytic substrate for angiotensin-converting enzyme 2, the key severe acute respiratory syndrome receptor. The in vivo physiological role of Apelin is still elusive. Here we report the generation of Apelin gene-targeted mice. Apelin mutant mice are viable and fertile, appear healthy, and exhibit normal body weight, water and food intake, heart rates, and heart morphology. Intriguingly, aged Apelin knockout mice developed progressive impairment of cardiac contractility associated with systolic dysfunction in the absence of histological abnormalities. We also report that pressure overload induces upregulation of Apelin expression in the heart. Importantly, in pressure overload-induced heart failure, loss of Apelin did not significantly affect the hypertrophy response, but Apelin mutant mice developed progressive heart failure. Global gene expression arrays and hierarchical clustering of differentially expressed genes in hearts of banded Apelin(-/y) and Apelin(+/y) mice showed concerted upregulation of genes involved in extracellular matrix remodeling and muscle contraction. These genetic data show that the endogenous peptide Apelin is crucial to maintain cardiac contractility in pressure overload and aging.


Subject(s)
Aging/physiology , Blood Pressure/physiology , Carrier Proteins/genetics , Heart Failure/physiopathology , Myocardial Contraction/physiology , Adipokines , Aging/genetics , Animals , Aorta , Apelin , Blood Pressure/genetics , Carrier Proteins/metabolism , Disease Models, Animal , Drinking Behavior , Echocardiography , Feeding Behavior , Female , Heart/embryology , Heart/physiology , Heart Failure/diagnostic imaging , Homeostasis/physiology , Intercellular Signaling Peptides and Proteins , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Myocardial Contraction/genetics , Obesity/physiopathology , RNA, Messenger/metabolism , Severity of Illness Index
9.
Nature ; 444(7122): 1088-91, 2006 Dec 21.
Article in English | MEDLINE | ID: mdl-17167413

ABSTRACT

Angiotensin -converting enzyme 2 (ACE2) is a regulator of the renin angiotensin system involved in acute lung failure, cardiovascular functions and severe acute respiratory syndrome (SARS) infections in mammals. A gene encoding a homologue to ACE2, termed collectrin (Tmem27), has been identified in immediate proximity to the ace2 locus. The in vivo function of collectrin was unclear. Here we report that targeted disruption of collectrin in mice results in a severe defect in renal amino acid uptake owing to downregulation of apical amino acid transporters in the kidney. Collectrin associates with multiple apical transporters and defines a novel group of renal amino acid transporters. Expression of collectrin in Xenopus oocytes and Madin-Darby canine kidney (MDCK) cells enhances amino acid transport by the transporter B(0)AT1. These data identify collectrin as a key regulator of renal amino acid uptake.


Subject(s)
Amino Acid Transport Systems/metabolism , Amino Acids/metabolism , Kidney/metabolism , Membrane Glycoproteins/metabolism , Animals , Biological Transport , Cell Line , Cell Polarity , Dogs , Down-Regulation , Female , Male , Membrane Glycoproteins/deficiency , Membrane Glycoproteins/genetics , Mice , Mice, Inbred C57BL , Oocytes/metabolism , Tyrosine/metabolism , Xenopus
10.
Nature ; 440(7084): 692-6, 2006 Mar 30.
Article in English | MEDLINE | ID: mdl-16572175

ABSTRACT

Bone metastases are a frequent complication of many cancers that result in severe disease burden and pain. Since the late nineteenth century, it has been thought that the microenvironment of the local host tissue actively participates in the propensity of certain cancers to metastasize to specific organs, and that bone provides an especially fertile 'soil'. In the case of breast cancers, the local chemokine milieu is now emerging as an explanation for why these tumours preferentially metastasize to certain organs. However, as the inhibition of chemokine receptors in vivo only partially blocks metastatic behaviour, other factors must exist that regulate the preferential metastasis of breast cancer cells. Here we show that the cytokine RANKL (receptor activator of NF-kappaB ligand) triggers migration of human epithelial cancer cells and melanoma cells that express the receptor RANK. RANK is expressed on cancer cell lines and breast cancer cells in patients. In a mouse model of melanoma metastasis, in vivo neutralization of RANKL by osteoprotegerin results in complete protection from paralysis and a marked reduction in tumour burden in bones but not in other organs. Our data show that local differentiation factors such as RANKL have an important role in cell migration and the tissue-specific metastatic behaviour of cancer cells.


Subject(s)
Bone Neoplasms/metabolism , Bone Neoplasms/secondary , Carrier Proteins/metabolism , Cell Movement , Membrane Glycoproteins/metabolism , Neoplasm Metastasis/pathology , Animals , Bone Neoplasms/pathology , Breast Neoplasms/metabolism , Breast Neoplasms/pathology , Carrier Proteins/genetics , Cell Death , Cell Differentiation , Cell Line, Tumor , Cell Proliferation , Epithelial Cells/pathology , Female , Humans , Melanoma/metabolism , Melanoma/pathology , Membrane Glycoproteins/genetics , Mice , Organ Specificity , Paralysis , RANK Ligand , Receptor Activator of Nuclear Factor-kappa B , Signal Transduction
11.
Nature ; 436(7047): 112-6, 2005 Jul 07.
Article in English | MEDLINE | ID: mdl-16001071

ABSTRACT

Acute respiratory distress syndrome (ARDS), the most severe form of acute lung injury, is a devastating clinical syndrome with a high mortality rate (30-60%) (refs 1-3). Predisposing factors for ARDS are diverse and include sepsis, aspiration, pneumonias and infections with the severe acute respiratory syndrome (SARS) coronavirus. At present, there are no effective drugs for improving the clinical outcome of ARDS. Angiotensin-converting enzyme (ACE) and ACE2 are homologues with different key functions in the renin-angiotensin system. ACE cleaves angiotensin I to generate angiotensin II, whereas ACE2 inactivates angiotensin II and is a negative regulator of the system. ACE2 has also recently been identified as a potential SARS virus receptor and is expressed in lungs. Here we report that ACE2 and the angiotensin II type 2 receptor (AT2) protect mice from severe acute lung injury induced by acid aspiration or sepsis. However, other components of the renin-angiotensin system, including ACE, angiotensin II and the angiotensin II type 1a receptor (AT1a), promote disease pathogenesis, induce lung oedemas and impair lung function. We show that mice deficient for Ace show markedly improved disease, and also that recombinant ACE2 can protect mice from severe acute lung injury. Our data identify a critical function for ACE2 in acute lung injury, pointing to a possible therapy for a syndrome affecting millions of people worldwide every year.


Subject(s)
Carboxypeptidases/metabolism , Lung Diseases/enzymology , Lung Diseases/pathology , Acids/pharmacology , Acute Disease , Analysis of Variance , Angiotensin II/metabolism , Angiotensin-Converting Enzyme 2 , Animals , Capillary Permeability , Carboxypeptidases/deficiency , Carboxypeptidases/genetics , Disease Models, Animal , Gene Deletion , Humans , Lung/pathology , Lung/physiopathology , Lung Diseases/genetics , Lung Diseases/physiopathology , Mice , Mice, Knockout , Mice, Transgenic , Oxygen/blood , Peptidyl-Dipeptidase A , Pulmonary Edema/pathology , Pulmonary Edema/physiopathology , Receptor, Angiotensin, Type 1/metabolism , Receptor, Angiotensin, Type 2/metabolism , Respiratory Distress Syndrome/enzymology , Respiratory Distress Syndrome/genetics , Respiratory Distress Syndrome/pathology , Sepsis/enzymology , Sepsis/genetics , Sepsis/pathology , Transgenes/genetics
12.
Immunity ; 21(2): 167-77, 2004 Aug.
Article in English | MEDLINE | ID: mdl-15308098

ABSTRACT

Antigen-specific immunotolerance limits the expansion of self-reactive T cells involved in autoimmune diseases. Here, we show that the E3 ubiquitin ligase Cbl-b is upregulated in T cells after tolerizing signals. Loss of Cbl-b in mice results in impaired induction of T cell tolerance both in vitro and in vivo. Importantly, rechallenge of Cbl-b mutant mice with the tolerizing antigen results in massive lethality. Moreover, ablation of Cbl-b resulted in exacerbated autoimmunity. Mechanistically, loss of Cbl-b rescues reduced calcium mobilization of anergic T cells, which was attributed to Cbl-b-mediated regulation of PLCgamma-1 phosphorylation. Our results show a critical role for Cbl-b in the regulation of peripheral tolerance and anergy of T cells.


Subject(s)
Adaptor Proteins, Signal Transducing , Clonal Anergy/immunology , T-Lymphocytes/metabolism , Ubiquitin-Protein Ligases/metabolism , Adoptive Transfer , Animals , Antigens/immunology , Clonal Anergy/physiology , Enterotoxins/immunology , In Vitro Techniques , Mice , Phospholipase C gamma , Proto-Oncogene Proteins c-cbl , T-Lymphocytes/immunology , Type C Phospholipases/metabolism , Ubiquitin-Protein Ligases/immunology
13.
Circulation ; 108(17): 2147-52, 2003 Oct 28.
Article in English | MEDLINE | ID: mdl-12963636

ABSTRACT

BACKGROUND: We have recently shown that genetic inactivation of phosphoinositide 3-kinase gamma (PI3Kgamma), the isoform linked to G-protein-coupled receptors, results in increased cardiac contractility with no effect on basal cell size. Signaling via the G-protein-coupled beta-adrenergic receptors has been implicated in cardiac hypertrophy and heart failure, suggesting that PI3Kgamma might play a role in the pathogenesis of heart disease. METHODS AND RESULTS: To determine the role for PI3Kgamma in hypertrophy induced by G-protein-coupled receptors and cardiomyopathy, we infused isoproterenol, a beta-adrenergic receptor agonist, into PI3Kgamma-deficient mice. Compared with controls, isoproterenol infusion in PI3Kgamma-deficient mice resulted in an attenuated cardiac hypertrophic response and markedly reduced interstitial fibrosis. Intriguingly, chronic beta-adrenergic receptor stimulation triggered impaired heart functions in wild-type mice, whereas PI3Kgamma-deficient mice retained their increased heart function and did not develop heart failure. The lack of PI3Kgamma attenuated the activation of Akt/protein kinase B and extracellular signal-regulated kinase 1/2 signaling pathways in cardiac myocytes in response to isoproterenol. beta1- and beta2-adrenergic receptor densities were decreased by similar amounts in PI3Kgamma-deficient and control mice, suggesting that PI3Kgamma isoform plays no role in the downregulation of beta-adrenergic receptors after chronic beta-adrenergic stimulation. CONCLUSIONS: Our data show that PI3Kgamma is critical for the induction of hypertrophy, fibrosis, and cardiac dysfunction function in response to beta-adrenergic receptor stimulation in vivo. Thus, PI3Kgamma may represent a novel therapeutic target for the treatment of decreased cardiac function in heart failure.


Subject(s)
Heart Failure/enzymology , Heart Failure/prevention & control , Isoproterenol , Phosphatidylinositol 3-Kinases/deficiency , Adrenergic beta-Agonists , Animals , Cardiomegaly/chemically induced , Cardiomegaly/enzymology , Cardiomegaly/prevention & control , Catalytic Domain/genetics , Disease Models, Animal , Fibrosis/genetics , Fibrosis/pathology , Fibrosis/prevention & control , Heart/drug effects , Heart Failure/chemically induced , Heart Failure/pathology , Male , Mice , Mice, Knockout , Myocardium/enzymology , Myocardium/pathology , Phosphatidylinositol 3-Kinases/genetics , Signal Transduction/drug effects , Signal Transduction/genetics
14.
Hypertension ; 42(4): 749-53, 2003 Oct.
Article in English | MEDLINE | ID: mdl-12874086

ABSTRACT

Previously we demonstrated that kidney concentration and urinary excretion of angiotensin-(1-7) are increased during normal pregnancy in rats. Since this finding may reflect local kidney production of angiotensin-(1-7), we determined the immunocytochemical distribution of angiotensin-(1-7) and its newly described processing enzyme, ACE2, in kidneys of virgin and 19-day-pregnant Sprague-Dawley rats. Sprague-Dawley rats were killed at the 19th day of pregnancy, and tissues were prepared for immunocytochemical by using a polyclonal antibody to angiotensin- (1-7) or a monoclonal antibody to ACE2. Angiotensin-(1-7) immunostaining was predominantly localized to the renal tubules traversing both the inner cortex and outer medulla. ACE2 immunostaining was localized throughout the cortex and outer medulla and was visualized in the renal tubules of both virgin and pregnant rats. The quantification of angiotensin-(1-7) and ACE2 immunocytochemical staining showed that in pregnant animals, the intensity of the staining increased by 56% and 117%, respectively (P<0.05). This first demonstration of the immunocytochemical distribution of angiotensin-(1-7) and ACE2 in kidneys of pregnant rats shows that pregnancy increases angiotensin-(1-7) immunocytochemical expression in association with increased ACE2 intensity of staining. The findings suggest that ACE2 may contribute to the local production and overexpression of angiotensin-(1-7) in the kidney during pregnancy.


Subject(s)
Angiotensin II/metabolism , Carboxypeptidases/metabolism , Kidney/metabolism , Peptide Fragments/metabolism , Pregnancy, Animal/metabolism , Angiotensin I , Angiotensin II/analysis , Angiotensin II/immunology , Angiotensin-Converting Enzyme 2 , Animals , Carboxypeptidases/analysis , Carboxypeptidases/immunology , Female , Immunohistochemistry , Kidney/anatomy & histology , Kidney/chemistry , Peptide Fragments/analysis , Peptide Fragments/immunology , Peptidyl-Dipeptidase A , Pregnancy , Rats , Rats, Sprague-Dawley
15.
Science ; 300(5623): 1291-5, 2003 May 23.
Article in English | MEDLINE | ID: mdl-12764197

ABSTRACT

Meiosis is a critical stage of gametogenesis in which alignment and synapsis of chromosomal pairs occur, allowing for the recombination of maternal and paternal genomes. Here we show that FK506 binding protein (Fkbp6) localizes to meiotic chromosome cores and regions of homologous chromosome synapsis. Targeted inactivation of Fkbp6 in mice results in aspermic males and the absence of normal pachytene spermatocytes. Moreover, we identified the deletion of Fkbp6 exon 8 as the causative mutation in spontaneously male sterile as/as mutant rats. Loss of Fkbp6 results in abnormal pairing and misalignments between homologous chromosomes, nonhomologous partner switches, and autosynapsis of X chromosome cores in meiotic spermatocytes. Fertility and meiosis are normal in Fkbp6 mutant females. Thus, Fkbp6 is a component of the synaptonemal complex essential for sex-specific fertility and for the fidelity of homologous chromosome pairing in meiosis.


Subject(s)
Chromosome Pairing/physiology , Fertility/physiology , Infertility, Male/physiopathology , Meiosis , Synaptonemal Complex/physiology , Tacrolimus Binding Proteins/genetics , Tacrolimus Binding Proteins/physiology , Amino Acid Sequence , Animals , Apoptosis , Cell Cycle Proteins , Cloning, Molecular , DNA-Binding Proteins , Exons , Female , Gene Targeting , Humans , Infertility, Male/genetics , Male , Mice , Molecular Sequence Data , Mutation , Nuclear Proteins/genetics , Nuclear Proteins/metabolism , Oogenesis , Ovary/physiology , Prophase , Rats , Sequence Deletion , Spermatids/physiology , Spermatocytes/physiology , Spermatocytes/ultrastructure , Spermatogenesis , Tacrolimus Binding Proteins/chemistry , Testis/physiology , X Chromosome/physiology
16.
Cell ; 110(6): 737-49, 2002 Sep 20.
Article in English | MEDLINE | ID: mdl-12297047

ABSTRACT

The PTEN/PI3K signaling pathway regulates a vast array of fundamental cellular responses. We show that cardiomyocyte-specific inactivation of tumor suppressor PTEN results in hypertrophy, and unexpectedly, a dramatic decrease in cardiac contractility. Analysis of double-mutant mice revealed that the cardiac hypertrophy and the contractility defects could be genetically uncoupled. PI3Kalpha mediates the alteration in cell size while PI3Kgamma acts as a negative regulator of cardiac contractility. Mechanistically, PI3Kgamma inhibits cAMP production and hypercontractility can be reverted by blocking cAMP function. These data show that PTEN has an important in vivo role in cardiomyocyte hypertrophy and GPCR signaling and identify a function for the PTEN-PI3Kgamma pathway in the modulation of heart muscle contractility.


Subject(s)
Myocardial Contraction , Phosphatidylinositol 3-Kinases/metabolism , Phosphoric Monoester Hydrolases/metabolism , Signal Transduction , Tumor Suppressor Proteins/metabolism , Adrenergic beta-Agonists/pharmacology , Animals , Cardiomegaly/genetics , Cardiomegaly/physiopathology , Cell Size , Cells, Cultured , Cyclic AMP/metabolism , Dose-Response Relationship, Drug , Ethanolamines/pharmacology , GTP-Binding Proteins/metabolism , Gene Expression Regulation , Genes, Tumor Suppressor , Mice , Mice, Mutant Strains , Mice, Transgenic , Myocardium/metabolism , PTEN Phosphohydrolase , Phosphatidylinositol 3-Kinases/chemistry , Phosphatidylinositol 3-Kinases/genetics , Phosphorylation , Protein Serine-Threonine Kinases/metabolism , Proto-Oncogene Proteins/metabolism , Proto-Oncogene Proteins c-akt
17.
Nature ; 417(6891): 822-8, 2002 Jun 20.
Article in English | MEDLINE | ID: mdl-12075344

ABSTRACT

Cardiovascular diseases are predicted to be the most common cause of death worldwide by 2020. Here we show that angiotensin-converting enzyme 2 (ace2) maps to a defined quantitative trait locus (QTL) on the X chromosome in three different rat models of hypertension. In all hypertensive rat strains, ACE2 messenger RNA and protein expression were markedly reduced, suggesting that ace2 is a candidate gene for this QTL. Targeted disruption of ACE2 in mice results in a severe cardiac contractility defect, increased angiotensin II levels, and upregulation of hypoxia-induced genes in the heart. Genetic ablation of ACE on an ACE2 mutant background completely rescues the cardiac phenotype. But disruption of ACER, a Drosophila ACE2 homologue, results in a severe defect of heart morphogenesis. These genetic data for ACE2 show that it is an essential regulator of heart function in vivo.


Subject(s)
Drosophila Proteins , Heart/physiology , Myocardium/enzymology , Peptidyl-Dipeptidase A/metabolism , Angiotensin II/blood , Angiotensin II/metabolism , Animals , Blood Pressure/genetics , Cloning, Molecular , Drosophila melanogaster/enzymology , Drosophila melanogaster/genetics , Drosophila melanogaster/physiology , Female , Gene Deletion , Gene Expression Regulation, Enzymologic , Heart/physiopathology , Hypertension/genetics , Hypoxia/genetics , Male , Metalloendopeptidases/deficiency , Metalloendopeptidases/genetics , Metalloendopeptidases/metabolism , Mice , Mice, Knockout , Myocardial Contraction , Peptidyl-Dipeptidase A/deficiency , Peptidyl-Dipeptidase A/genetics , Quantitative Trait, Heritable , Radiation Hybrid Mapping , Rats , Up-Regulation , X Chromosome/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...